HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Inclusion Criteria

• •1. Age range of 18-75 years old (inclusive of both ends), gender not limited when signing the informed consent form
• •2. ECOG performance status 0 or 1
• •3. Life expectancy of greater than or equal to 12 weeks.
• •4. Subjects with unresectable local advanced or metastatic pancreatic cancer, and pancreatic duct adenocarcinoma confirmed by histopathology
• •5. Provide tumor tissue blocks fixed in formalin, embedded in paraffin, or unstained tumor specimen sections, which can be archived or freshly obtained within 3 years prior to the first study treatment (fresh acquisition is preferred).
• •6. At least one measurable lesion is present according to the efficacy evaluation criteria for pancreatic cancer (RECIST 1.1)